News

Hybio Wuhan Partners with GenTech to Forge New Paths in Peptide Industry Waste Liquid Resource Recovery

With the surge in global market demand for GLP-1 (Glucagon-like peptide-1) drugs, domestic peptide production capacity continues to expand. Consequently, the treatment of massive amounts of backend production waste liquid is becoming a critical bottleneck re...

HYBIO Pharmaceutical and MCG Pharma signed product licensing agreement to jointly expand the Turkish market

On April 10, 2026, Shenzhen Hybio Pharmaceutical Co., Ltd. ("Hybio Pharma") and MCG Pharma İlaç Sanayi ve Ticaret Limited Şirketi ("MCG Pharma"), a well-known Turkish pharmaceutical and healthcare company, successfully held a licensing agreement s...

Good News | Hybio Pharmaceutical Receives U.S. FDA Approval for Glatiramer

February 11, 2026 — Hybio Pharmaceutical Co., Ltd. announced today that its self-developed Glatiramer Acetate Injection has received marketing approval from the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS). Thi...

Good News | HYBIO Pharmaceutical Completes Official NMPA Registration of Semaglutide API

Recently, a public disclosure by China’s National Medical Products Administration (NMPA) indicated that Hybio Pharmaceutical (Wuhan) Co., Ltd. has completed the official registration of its semaglutide active pharmaceutical ingredient (API) (Registrati...

Good News | Hybio Pharmaceutical Completes Official NMPA Registration for Tirzepatide API

Recently, the National Medical Products Administration (NMPA) information platform published an update showing that Hybio Pharmaceutical (Wuhan) Co., Ltd. has completed the official registration for its Tirzepatide active pharmaceutical ingredient (API) (R...

Hybio Pharmaceutical and Dr. Reddy’s Sign non-binding strategic cooperation term sheet on Peptide APIs to Advance Global Peptide Collaboration

December 25 — Hybio Pharmaceutical and Dr. Reddy’s Laboratories Limited (referred to as “Dr. Reddy’s”), a global pharmaceutical company, held a signing ceremony in Beijing, where the two parties formally executed a non-binding...

HYBIO Pharmaceutical Takes a Strategic Minority Stake in iCarbonX to Strengthen AI-Peptide R&D and Industrialization Collaboration

HYBIO Pharmaceutical Co., Ltd. (“HYBIO Pharmaceutical”) has entered into a strategic investment partnership with Shenzhen iCarbonX Intelligent Technology Co., Ltd. (“iCarbonX”). Under the agreement, HYBIO Pharmaceutical will invest RM...

Hybio Pharmaceutical’s Longhua Headquarters R&D Center Laboratory Passes FDA Inspection Again with “Zero Deficiencies”

On December 5, 2025, the laboratory at the R&D Center of Hybio Pharmaceutical’s Longhua Headquarters successfully passed an on-site inspection by the U.S. Food and Drug Administration (FDA) with a “zero-deficiency” result—receiving ...

Dr. Reddy’s Global CEO Leads Delegation to Hybio, Mapping Out International Peptide Partnership

Hybio Pharmaceutical and Institute of Process Engineering, Chinese Academy of Sciences Enter into Strategic Cooperation to Jointly Establish "Innovation Consortium for Industrial Transformation of Hig

On August 20,2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and the Institute of Process Engineering, Chinese Academy of Sciences (referred to as "IPE-CAS") officially signed a strategic cooperation agreement to jointly build the "Innovation Consortium for Industrial Transformation of High-End Peptide Sustained-Release Preparations". 

Hybio Pharmaceutical and Sunshine Mandi Pharmaceutical Sign a Series of Commercial Agreements, Accelerating the Progress of Weight-Loss Drugs Across the Board

Beijing, August 19, 2025. Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (referred to as "Sunshine Mandi") officially signed a series of commercial documents in Beijing today

Hybio Pharmaceutical and KuCoin Join Forces to Pioneer China’s First RWA Pilot in Innovative Drug Development

On August 4, 2025, Hybio Pharmaceutical and KuCoin, a world-leading digital asset platform, formally signed a strategic cooperation letter of intent. Both parties plan to jointly explore and advance the first RWA (Real World Asset) tokenization pilot project in Hong Kong with "future income rights from innovative drug R&D" as the underlying asset, originating from the Chinese mainland.

Hybio Pharmaceutical and BrightGene Pharmaceutical Enter into Strategic Cooperation to Safeguard Overseas Supply Chains for Innovative Drugs

Hybio Pharmaceutical and iCarbonX Intelligent Peptide Deepen Strategic Cooperation, Signing Two Agreements on Innovative Drug CRDMO Services and Strategic Investment

Academician Ma Guanghui of the Chinese Academy of Sciences and His Delegation Visited Hybio Pharmaceutical to Explore the Development of Long-Acting High-Effect Innovative Peptide Formulations